Huntington's disease may become a new weapon against cancer March 13, 2018 Source: CPhI Pharma Online Author: The red leaf Huntington's disease Huntington's disease is an autosomal dominant neurodegenerative disease, a fatal hereditary disease that causes brain cell death in the brain. Huntington's disease causes the body and mental retardation to occur at the optimal working age. And can't be cured. It usually occurs around 40 to 50 years old, with an average survival of 15 to 20 years after onset. Huntington's disease is generally fatal and there is no effective treatment. However, compared with the general population, Huntington's disease patients can be reduced by up to 80%. To clarify the relationship between Huntington's disease and cancer, scientists at Northwestern Medicine have discovered why Huntington's disease is highly toxic to cancer cells and use this to find new ways to treat cancer. The pathogenesis of Huntington's disease Huntington's disease is caused by the presence of an excess of specific RNA repeats on the gene encoding the huntingtin protein, which is present in all cells. This deficiency, which causes disease, is also highly toxic to tumor cells. These repeats -- in the form of so-called small interfering RNA -- attack certain genes in the cell that are vital to survival. Neurons in the brain are prone to this form of cell death, but cancer cells appear to be more susceptible to infection. Senior author Marcus Peter said: "This molecule is a super killer of all tumor cells, and we have never seen such a powerful thing." The study was published in the February 12 issue of the European Journal of Molecular Biology. Nanotechnology boosts treatment methods To test the therapeutic effects of this super killer, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule through nanoparticles to mice with human ovarian cancer. This treatment significantly slows tumor growth and is not toxic to mice. Importantly, the tumor does not develop resistance to this cancer treatment. Peter and Thaxton are currently optimizing the way molecules are delivered to increase their efficiency in reaching tumors. Another challenge scientists face is finding ways to stabilize the nanoparticles so they can be preserved. The researchers also use this molecule to treat human and mouse ovarian cancer, breast cancer, prostate cancer, liver cancer, brain cell tumors, skin cancer, and colon cancer cell lines. This molecule kills all cancer cells from both species. " Death switch" raises concerns about the anti-cancer effect of Huntington's disease Huntington's cancer weapon was discovered by Murmann, who had an early study with Peter and found that all cells that destroy cancer cells have a switch that specifically kills cancer cells. Murmann had previously envisioned that perhaps in some people, this death switch was overactive, causing tissue loss. These patients must not only have diseases involving RNA components, but must also be less susceptible to cancer. Huntington's disease is the most obvious disease that meets these two characteristics. The study found that the repeats in the Huntingtin gene have similar sequences to the previously discovered death switches, both of which are rich in C and G nucleotides (the basic molecules that make up DNA and RNA). This similarity has caused scientists' curiosity. In Huntington's disease patients, the Huntingtin gene contains an excess of CAG trinucleotide repeats. The longer the repeat sequence, the sooner the patient becomes ill. Researchers are currently developing short-term cancer therapies for weeks, in which they can treat patients and kill cancer cells without causing the neurological symptoms of Huntington's patients. Huntington's disease spreads all over the world and affects all ethnic groups. Among them, Caucasians in Europe and America are involved, and the incidence rate is different. There are regional clusters. The research on the pathogenic mechanism of Huntington's disease in China has not been carried out in depth. Activation of the apoptotic pathway is considered to be one of the pathogenesis of Huntington's disease and has become an important and interesting therapeutic target. However, there are few studies between the pathogenesis of Huntington's disease and cancer, and the publication of this study will point the way to the cause of human cancer treatment. Source: https://medicalxpress.com/news/2018-02-huntington-disease-cancer-weapon.html The characteristics of POCT devices determine that they can play an important role in primary medical institutions. In order to standardize and strengthen the application of on-site rapid testing in primary medical and health institutions, promote the rational allocation, safe and effective use of POCT in primary medical and health institutions, give full play to its use value, and ensure the healthy development of medical and health services, "On-site Point-of-care Testing (POCT) Primary The Expert Consensus on the Application of Medical and Health Institutions (hereinafter referred to as the "Consensus") came into being. The consensus was published in the 2019 "China Medical Equipment" magazine after first draft writing, 2 expert on-site discussions, 2 expert online review meetings, and 3 submission revisions. The formulation of the consensus will greatly promote the management standards of the POCT industry, continuously increase the training of grass-roots personnel, deeply understand the application requirements of POCT at the grass-roots level, and promote the rapid development of the POCT industry. Portable Analyzer for Blood Fat,Home Care Blood Glucose Meter,Best Blood Glucose Meter,Blood Glucose Meter Device Jilin Sinoscience Technology Co. LTD , https://www.jlgkscience.com
Point-of-care testing (POCT) represents a fruitful method in today's hospitals in terms of patient care and cost management. Its application enables some of the testing items originally undertaken by the central laboratory to be transferred to the clinical departments and patient beds that need it. side. For blood gas analysis technology, POCT has shown great advantages.
Our blood gas analyzer is small and portable, beautiful in appearance, accurate in results and good in stability. It is a blood gas analysis platform with both appearance and strength. It can be used not only in the central laboratory department, but also at the bedside of patients to meet the bedside detection needs of clinical departments such as hospital ICU, emergency, anesthesia, respiratory, neurology, etc. It realizes true POCT blood gas analysis and provides more advantageous assistance for clinical practice. Diagnostic Services.
Huntington's disease may become a new weapon against cancer